Investigational drug · Phase 2
AZD5004
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity or Overweight, Diabetes Mellitus, Type 2.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
14
Any phase or sponsor naming "AZD5004"
First trial start
2024
Oct 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5004", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Obesity or Overweight
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5004" as an intervention, largest first.
- Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06579105 · 406 participants · Start Oct 8, 2024 · Primary completion Dec 19, 2025
Drug: Placebo (placebo matching AZD5004 film-coated tablet); AZD5004 and 1 more · For: Diabetes Mellitus, Type 2
Sites: Mobile, Alabama; Sheffield, Alabama; Vestavia Hills, Alabama · 97 sites in all
- A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07775404 · 351 participants (planned) · Start Aug 21, 2026 · Primary completion Apr 6, 2028
Drug: Elecoglipron; Placebo · For: Obesity; Overweight
Sites: Baotou, China; Beijing, China; Changde, China · 49 sites in all
- Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related ComorbidityPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06579092 · 310 participants · Start Oct 8, 2024 · Primary completion Nov 21, 2025
Drug: AZD5004; Placebo · For: Obesity or Overweight
Sites: Chandler, Arizona; Huntington Park, California; La Mesa, California · 62 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07455825 · 65 participants · Start Mar 5, 2026 · Primary completion Jun 1, 2026
Drug: AZD5004 · For: Healthy Participants
Sites: Glendale, California; Baltimore, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06942936 · 51 participants · Start May 28, 2025 · Primary completion Jan 28, 2026
Drug: AZD5004; Itraconazole and 1 more · For: Healthy Participants
Sites: Baltimore, Maryland; Berlin, Germany
AstraZenecaAstraZeneca (AZN)
NCT06948747 · 49 participants · Start May 6, 2025 · Primary completion Oct 3, 2025
Drug: AZD5004; Rosuvastatin and 4 more · For: Healthy Participants
Sites: Brooklyn, Maryland
EccogeneIndustry
NCT06988553 · 45 participants · Start Jun 17, 2025 · Primary completion Nov 28, 2025
Drug: AZD5004; Placebo · For: Obesity or Overweight; Type 2 Diabetes
Sites: Chengdu, China; Ha’erbin, China; Hefei, China · 6 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06703658 · 35 participants · Start Nov 2, 2024 · Primary completion Mar 13, 2025
Drug: AZD5004(Part A); Placebo(Part A) and 2 more · For: Healthy Participants; Type 2 Diabetes
Sites: Osaka, Japan
AstraZenecaAstraZeneca (AZN)
NCT06813781 · 33 participants · Start Dec 19, 2024 · Primary completion Oct 2, 2025
Drug: AZD5004 · For: Hepatic Impairment
Sites: Lake Forest, California; Rialto, California; Miami Lakes, Florida · 5 sites in all
- A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy ParticipantsCompleted
AstraZenecaAstraZeneca (AZN)
NCT07444424 · 32 participants · Start Mar 13, 2026 · Primary completion Jul 2, 2026
Drug: AZD5004; Mitiglinide and 1 more · For: Healthy Participants
Sites: Fukuoka, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1, open-label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions.
Xu J, Haggag A, Butcher L, et al. · Br J Clin Pharmacol 2026
- Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
Davies MJ, Aroda VR, Rosenstock J, et al. · Lancet 2026
- Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Haggag AZ, Xu J, Butcher L, et al. · Diabetes Obes Metab 2025
Also in development for Obesity or Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- TifeglipronRO7795081, CT-996Phase 22 trials
Roche (Genentech) · Type 2 Diabetes Mellitus, Obesity or Overweight
- RGT001-075Phase 21 trial
Regor Pharmaceuticals Inc. · Obesity or Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.